Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that Daniel O. Claassen, MD, PhD, has been appointed chief medical advisor.
In addition to this role, Dr. Claassen will retain his academic appointment as tenured professor at Vanderbilt University Medical Center. He is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in movement disorders and cognitive and behavioral neurology.
In a statement, David Stamler, MD, CEO of Alterity, commented, “I am thrilled to welcome Dr. Claassen as our new chief medical advisor, bringing deep clinical and development expertise to our organization at a pivotal time for Alterity. Daniel’s highly distinguished track record focused on patient care and clinical trial conduct in neurodegenerative diseases will be invaluable as we advance ATH434 into Phase 3. Daniel was the coordinating investigator for our Phase 2 study and has been a key contributor to our ATH434 program in multiple system atrophy from the outset, so he is exceptionally well qualified to help guide our next phase of growth and execution.”
One layout suggestion: I can move the contact tables to page 12 and make them a standalone “Contacts” section (instead of spanning pages 11–12 within “Leverage the Profound Organization”).
